NumFin

Sansure Biotech Inc.

Sümbol: 688289.SS

SHH

20.62

CNY

Turuhind täna

  • 31.0215

    P/E suhe

  • 0.0048

    PEG suhe

  • 11.83B

    MRK Cap

  • 0.03%

    DIV tootlus

Sansure Biotech Inc. (688289-SS) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete Sansure Biotech Inc. (688289.SS) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes Sansure Biotech Inc. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

balance-sheet.row.cash-and-short-term-investments

04781.85663.84682.7
4192
165.5
127
39.9

balance-sheet.row.short-term-investments

0548.32451.22046.5
1601.2
66.3
0
0

balance-sheet.row.net-receivables

0732.81472.7894.1
606.7
195.6
171.1
134.1

balance-sheet.row.inventory

0376.6355.3369.5
276.7
64.7
55.9
40.9

balance-sheet.row.other-current-assets

058.433.620
7.2
11.5
5.1
103.6

balance-sheet.row.total-current-assets

05949.67525.45966.2
5082.7
437.2
359.1
318.4

balance-sheet.row.property-plant-equipment-net

01055.2785.3481
216.5
176.5
162.7
161.1

balance-sheet.row.goodwill

07.700
0
0
0
0

balance-sheet.row.intangible-assets

032884.445.6
31.2
11.5
11.2
10.7

balance-sheet.row.goodwill-and-intangible-assets

0335.684.445.6
31.2
11.5
11.2
10.7

balance-sheet.row.long-term-investments

0974.3-1793.8-1533.2
-1498.7
4.8
3.4
4

balance-sheet.row.tax-assets

073.869.625
17.2
11.5
11.9
15.8

balance-sheet.row.other-non-current-assets

065.62502.82105.8
1605.4
1
3.6
55.6

balance-sheet.row.total-non-current-assets

02504.61648.31124.1
371.7
205.3
192.9
247.2

balance-sheet.row.other-assets

0000
0
0
0
0

balance-sheet.row.total-assets

08454.29173.87090.4
5454.4
642.5
552
565.6

balance-sheet.row.account-payables

0468.7791.4258.7
272.3
35.3
42.6
21.6

balance-sheet.row.short-term-debt

077.214.38.5
55
-6.6
0
0

balance-sheet.row.tax-payables

017.7216.4101.3
112.1
4.7
4
1.9

balance-sheet.row.long-term-debt-total

018.213.66.4
3.2
0
0
0

Deferred Revenue Non Current

032.530.525.7
19
11.4
10.6
10.1

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-

balance-sheet.row.other-current-liab

0340.5712.92.4
3.3
38.1
102.6
99.3

balance-sheet.row.total-non-current-liabilities

077.789.345.1
20.3
11.6
10.6
65.7

balance-sheet.row.other-liabilities

0000
0
0
0
0

balance-sheet.row.capital-lease-obligations

018.213.66.4
3.2
0
0
0

balance-sheet.row.total-liab

0996.81661709
708.9
85
155.8
186.6

balance-sheet.row.preferred-stock

0000
0
0
0
0

balance-sheet.row.common-stock

0588.5588.5400
400
360
127.9
127.9

balance-sheet.row.retained-earnings

04882.75077.13820
2026.6
-28.2
-300.4
-307.1

balance-sheet.row.accumulated-other-comprehensive-income-loss

0395.2377.4294
263.8
0
0
0

balance-sheet.row.other-total-stockholders-equity

01334.91457.71854.9
2054.9
225.7
568.8
558.3

balance-sheet.row.total-stockholders-equity

07201.37500.66368.9
4745.4
557.5
396.3
379

balance-sheet.row.total-liabilities-and-stockholders-equity

08454.29173.87090.4
5454.4
642.5
552
565.6

balance-sheet.row.minority-interest

0223.612.212.4
0
0
0
0

balance-sheet.row.total-equity

07424.97512.86381.3
4745.4
557.5
396.3
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-

Total Investments

01522.6657.4513.2
102.5
66.3
3.4
4

balance-sheet.row.total-debt

095.427.914.9
55
0
0
0

balance-sheet.row.net-debt

0-4138-3184.7-2621.3
-2535.8
-99.2
-127
-39.9

Rahavoogude aruanne

Sansure Biotech Inc. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM202220212020201920182017

cash-flows.row.net-income

01936.72242.52616.6
39.5
6.8
-10.7

cash-flows.row.depreciation-and-amortization

089.153.926.7
20.6
20.1
19.4

cash-flows.row.deferred-income-tax

0-40-8.1-4.6
0.7
0
0

cash-flows.row.stock-based-compensation

060.85.64.6
7.8
0
0

cash-flows.row.change-in-working-capital

0203.3-402.1-50.4
-49.7
-28.1
-90

cash-flows.row.account-receivables

0-496.5-304.1-419.4
-33.8
0
0

cash-flows.row.inventory

0-282.1-93-212.1
-8.8
-15.1
-0.3

cash-flows.row.account-payables

0496.53.1585.7
-7.8
0
0

cash-flows.row.other-working-capital

0485.4-8.1-4.6
0.7
-13
-89.7

cash-flows.row.other-non-cash-items

0308.9-14.849.4
3.5
11.3
19.8

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-558.8-372.9-108.7
-34.1
-32.9
-20.7

cash-flows.row.acquisitions-net

0-11.615.9115
0.4
0.6
0

cash-flows.row.purchases-of-investments

0-12140.6-7880-3725
-195
-100
-0.9

cash-flows.row.sales-maturities-of-investments

011591.17125.62111.3
130.9
100.7
0

cash-flows.row.other-investing-activites

0-46.9-0.9-108.7
3.2
109.1
-44.2

cash-flows.row.net-cash-used-for-investing-activites

0-1166.7-1112.2-1716
-94.6
77.5
-65.7

cash-flows.row.debt-repayment

0-17.2-55-55
0
0
-109.4

cash-flows.row.common-stock-issued

0274.62000
0
0
0

cash-flows.row.common-stock-repurchased

0-257.4-2000
0
0
0

cash-flows.row.dividends-paid

0-656.9-439.9-301.3
0
0
-5.6

cash-flows.row.other-financing-activites

0-259-193.71966.2
44.4
0
262.3

cash-flows.row.net-cash-used-provided-by-financing-activities

0-915.9-688.61609.9
44.4
0
147.3

cash-flows.row.effect-of-forex-changes-on-cash

0-10-34.3-44.6
0
-0.1
-0.1

cash-flows.row.net-change-in-cash

0466.2422491.6
-27.8
87.5
20

cash-flows.row.cash-at-end-of-period

03099.12632.82590.8
99.2
127
39.5

cash-flows.row.cash-at-beginning-of-period

02632.82590.899.2
127
39.5
19.5

cash-flows.row.operating-cash-flow

02558.91877.12642.3
22.4
10.1
-61.4

cash-flows.row.capital-expenditure

0-558.8-372.9-108.7
-34.1
-32.9
-20.7

cash-flows.row.free-cash-flow

02000.11504.22533.6
-11.7
-22.8
-82.1

Kasumiaruande rida

Sansure Biotech Inc. tulud muutusid võrreldes eelmise perioodiga NaN%. 688289.SS brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017

income-statement-row.row.total-revenue

01002.56450.44514.5
4763
365.4
303.4
224.6

income-statement-row.row.cost-of-revenue

0381.82655.41279
970
127.3
126
112.7

income-statement-row.row.gross-profit

0620.737953235.5
3793
238.1
177.4
111.9

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.other-expenses

010.695.544.5
39.6
14.7
-1
30.4

income-statement-row.row.operating-expenses

0638.71262.2666.9
680.9
188.7
163.7
127.1

income-statement-row.row.cost-and-expenses

01020.53917.51945.9
1650.8
316
289.8
239.8

income-statement-row.row.interest-income

054.748.432.5
16.7
0.2
5.1
6.1

income-statement-row.row.interest-expense

02.42.10.8
0.5
0.5
3.2
16.4

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0450.7-23.9-5.6
-15.9
-2.1
-3
17.9

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-

income-statement-row.row.other-operating-expenses

010.695.544.5
39.6
14.7
-1
30.4

income-statement-row.row.total-operating-expenses

0450.7-23.9-5.6
-15.9
-2.1
-3
17.9

income-statement-row.row.interest-expense

02.42.10.8
0.5
0.5
3.2
16.4

income-statement-row.row.depreciation-and-amortization

0136.8290.8-20.7
25.8
21.4
20.1
19.4

income-statement-row.row.ebitda-caps

0---
-
-
-
-

income-statement-row.row.operating-income

0-182339.82621.8
3086
47.5
11.7
-27.7

income-statement-row.row.income-before-tax

0432.62315.92616.2
3070.2
45.5
10.7
2.6

income-statement-row.row.income-tax-expense

062.3379.2373.7
453.6
6
3.9
13.3

income-statement-row.row.net-income

0363.71936.82242.7
2616.6
39.5
6.8
-10.7
Sarnased aktsiad
Sind võib huvitada ka:
CNVVF
ConvaTec Group Plc.
3.2 USD
PNK
300753.SZ
Jiangsu Apon Medical Technology Co., Ltd..
13.2 CNY
SHZ
BLCO
Bausch + Lomb Corporation.
15.29 USD
NYSE
137310.KS
SD BioSensor, Inc.
10740 KRW
KSC
YPHDF
Ypsomed Holding AG.
362 USD
PNK
INFU
InfuSystem Holdings, Inc..
7.56 USD
AMEX
7780.T
Menicon Co., Ltd..
1516.5 JPY
JPX
ALC.SW
Alcon Inc..
72.94 CHF
SIX
8086.T
Nipro Corporation.
1256 JPY
JPX
6929.HK
OrbusNeich Medical Group Holdings Limited.
4.42 HKD
HKSE

Korduma kippuv küsimus

Mis on Sansure Biotech Inc. (688289.SS) koguvara?

Sansure Biotech Inc. (688289.SS) koguvara on 8454204974.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.729.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -0.496.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.321.

Mis on ettevõtte kogutulu?

Kogutulu on 0.334.

Mis on Sansure Biotech Inc. (688289.SS) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 363721131.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 95444005.000.

Mis on tegevuskulude arv?

Tegevuskulud on 638676546.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 0.000.